Form 4: Enanta Pharmaceuticals Executive Brendan Luu Reports Stock Transaction
SEC Form 4 Filing
Chief Business Officer of Enanta Pharmaceuticals, Brendan Luu, forfeited 753 shares of common stock to cover withholding taxes.
Summary
- Brendan Luu, Chief Business Officer at Enanta Pharmaceuticals, forfeited 753 shares of common stock on December 1, 2024.
- The shares were forfeited to cover withholding taxes related to the settlement of a restricted stock unit award granted on November 19, 2021.
- Following the transaction, Luu directly owns 38,330 shares of Enanta Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.
Industry Context
This is a routine filing related to executive compensation and is common for publicly traded companies.
Comparison to Industry Standards
- Stock forfeitures to cover taxes are a standard practice in executive compensation across the pharmaceutical industry.
- Similar transactions are regularly reported by executives at comparable companies such as Vertex Pharmaceuticals and Gilead Sciences.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 2021-11-19 | Date of the restricted stock unit award grant. |
| 2024-12-01 | Date of the stock forfeiture transaction. |
| 2024-12-03 | Date the Form 4 was signed. |
Keywords
Enanta Pharmaceuticals, Brendan Luu, stock transaction, Form 4, insider trading, restricted stock unit, withholding taxes
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.